Journal Home
Search for

Volume 14, Issue 5, Pages 499-509 (May 2008)


View previous. 6 of 18 View next.

The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T Cells

Heather J. Symons12, Moshe Y. Levy13, Jie Wang1, Xiaotao Zhou1, Gang Zhou1, Sarah E. Cohen4, Leo Luznik3, Hyam I. Levitsky13, Ephraim J. Fuchs13Corresponding Author Informationemail address

Received 2 July 2007; accepted 11 February 2008.

Abstract 

The “allogeneic effect” refers to the induction of host B cell antibody synthesis or host T cell cytotoxicity, including tumoricidal activity, by an infusion of allogeneic lymphocytes. We show that treatment of mice with cyclophosphamide (Cy) followed by CD8+ T cell-depleted allogeneic donor lymphocyte infusion (Cy + CD8 DLI) induces regression of established tumors with minimal toxicity in models of both hematologic and solid cancers, even though the donor cells are eventually rejected by the host immune system. The optimal antitumor effect of Cy + CD8 DLI required the presence of donor CD4+ T cells, host CD8+ T cells, and alloantigen expression by normal host but not tumor tissue. The results support a model in which a donor CD4+ T cell-mediated graft-versus-host (GVH) reaction effectively awakens antitumor immunity among Cy-resistant host CD8+ T cells. These events provide the cellular mechanism of the “allogeneic effect” in antitumor immunity. Cy + CD8 DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers.

1 Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

2 Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

3 Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

4 Thomas Jefferson Medical College, Philadelphia, Pennsylvania

Corresponding Author InformationCorrespondence and reprint requests: Ephraim Joseph Fuchs, MD, 488 Blunting-Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231

PII: S1083-8791(08)00072-4

doi:10.1016/j.bbmt.2008.02.013


View previous. 6 of 18 View next.